Jyong Biotech Ltd.
MENS
$55.24
$1.182.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.59% | -17.19% | 1.84% | 6.93% | 12.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.49% | -14.98% | -3.16% | -2.12% | -1.13% |
| Operating Income | 26.49% | 14.98% | 3.16% | 2.12% | 1.13% |
| Income Before Tax | 31.39% | 35.35% | 38.06% | 35.81% | 33.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.39% | 35.35% | 38.06% | 35.81% | 33.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.39% | 35.35% | 38.06% | 35.81% | 33.63% |
| EBIT | 26.49% | 14.98% | 3.16% | 2.12% | 1.13% |
| EBITDA | 27.49% | 15.48% | 3.12% | 2.21% | 1.33% |
| EPS Basic | 31.49% | 35.36% | 38.00% | 35.78% | 33.62% |
| Normalized Basic EPS | 31.25% | 35.31% | 38.08% | 35.90% | 33.79% |
| EPS Diluted | 31.49% | 35.36% | 38.00% | 35.78% | 33.62% |
| Normalized Diluted EPS | 31.25% | 35.31% | 38.08% | 35.90% | 33.79% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |